Exacerbations in COPD: What’s the risk?
How does an exacerbation affect patient quality of life and lung function?
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
83% of COPD Triple Therapy patients in UK are managing once and twice daily dosing concurrently1
Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.3